FCCC LOGO Faculty Publications
Haddad RI , Lydiatt WM , Ball DW , Busaidy NL , Byrd D , Callender G , Dickson P , Duh QY , Ehya H , Haymart M , Hoh C , Hunt JP , Iagaru A , Kandeel F , Kopp P , Lamonica DM , McCaffrey JC , Moley JF , Parks L , Raeburn CD , Ridge JA , Ringel MD , Scheri RP , Shah JP , Smallridge RC , Sturgeon C , Wang TN , Wirth LJ , Hoffmann KG , Hughes M
Anaplastic Thyroid Carcinoma, Version 2.2015
J Natl Compr Canc Netw. 2015 Sep;13(9) :1140-1150
PMID: 26358798    PMCID: PMC4986600    URL: https://www.ncbi.nlm.nih.gov/pubmed/26358798
Back to previous list
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Notes
Haddad, Robert I. Lydiatt, William M. Ball, Douglas W. Busaidy, Naifa Lamki Byrd, David Callender, Glenda Dickson, Paxton Duh, Quan-Yang Ehya, Hormoz Haymart, Megan Hoh, Carl Hunt, Jason P. Iagaru, Andrei Kandeel, Fouad Kopp, Peter Lamonica, Dominick M. McCaffrey, Judith C. Moley, Jeffrey F. Parks, Lee Raeburn, Christopher D. Ridge, John A. Ringel, Matthew D. Scheri, Randall P. Shah, Jatin P. Smallridge, Robert C. Sturgeon, Cord Wang, Thomas N. Wirth, Lori J. Hoffmann, Karin G. Hughes, Miranda